Treatment Efficacy of MEDI3902 in Pseudomonas aeruginosa Bloodstream Infection and Acute Pneumonia Rabbit Models

Autor: Henry Clay Carter, Hoan N. Le, Binh An Diep, Vien T. M. Le, Fábio Aguiar-Alves, C. Kendall Stover, Trang Vu, Emmanuelle Gras, Bret R. Sellman, Erika Schneider-Smith, Marcos Gabriel Pinheiro, Vuvi G. Tran, Antonio DiGiandomenico
Jazyk: angličtina
Rok vydání: 2019
Předmět:
Cystic Fibrosis
bloodstream infections
medicine.medical_treatment
Bacteremia
Drug resistance
medicine.disease_cause
Type three secretion system
Antibodies
Bispecific
2.2 Factors relating to the physical environment
Pharmacology (medical)
Aetiology
Lung
0303 health sciences
Hematology
Pharmacology and Pharmaceutical Sciences
Treatment efficacy
Infectious Diseases
Treatment Outcome
5.1 Pharmaceuticals
Medical Microbiology
Pseudomonas aeruginosa
Pneumonia & Influenza
Bispecific
immunotherapy
Acute pneumonia
Immunotherapy
Rabbits
Development of treatments and therapeutic interventions
Infection
medicine.drug
Microbiology
Meropenem
Antibodies
03 medical and health sciences
Rare Diseases
medicine
pneumonia
Animals
Experimental Therapeutics
Pseudomonas Infections
030304 developmental biology
Pharmacology
030306 microbiology
business.industry
Prevention
Pneumonia
medicine.disease
business
Zdroj: Antimicrobial Agents and Chemotherapy
Antimicrobial agents and chemotherapy, vol 63, iss 8
ISSN: 1098-6596
0066-4804
Popis: Pseudomonas aeruginosa is a challenge for clinicians due to increasing drug resistance and dwindling treatment options. We report on the activity of MEDI3902, an antibody targeting type 3 secretion protein PcrV and Psl exopolysaccharide, in rabbit bloodstream and lung infection models. MEDI3902 prophylaxis or treatment was protective in both acute models and exhibited enhanced activity when combined with a subtherapeutic dose of meropenem.
Pseudomonas aeruginosa is a challenge for clinicians due to increasing drug resistance and dwindling treatment options. We report on the activity of MEDI3902, an antibody targeting type 3 secretion protein PcrV and Psl exopolysaccharide, in rabbit bloodstream and lung infection models. MEDI3902 prophylaxis or treatment was protective in both acute models and exhibited enhanced activity when combined with a subtherapeutic dose of meropenem. These findings further support MEDI3902 for the prevention or treatment of serious P. aeruginosa infections.
Databáze: OpenAIRE
Externí odkaz: